Critical analysis of the use of rituximab in mucous membrane pemphigoid: A review of the literature

Shetty, Shawn; Ahmed, A. Razzaque

doi:10.1016/j.jaad.2012.10.018

Cited by 48 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…83, 84 RTX can have dramatic efficacy in patients with severe, refractory MMP. 83, 85–89 RTX is a highly promising treatment option in MMP, but long-term follow-up after RTX therapy is lacking.…”

Section: Managementmentioning

confidence: 99%

Mucous Membrane Pemphigoid

Werth²,

Parisi³

et al. 2013

Dental Clinics of North America

145

150

View full text Add to dashboard Cite

Section: Managementmentioning

confidence: 99%

Mucous Membrane Pemphigoid

Werth²,

Parisi³

et al. 2013

Dental Clinics of North America

145

150

View full text Add to dashboard Cite

“…Explanation : Although only case reports have accumulated with low levels of evidence, the use of rituximab may be considered in patients who are resistant to conventional treatment. However, more than half of the relapses are observed 8–19 months after the initial dose . Furthermore, rituximab should not be used for diseases in which scars have already formed in the eyes and larynx and should be used early on, prior to cicatrization.…”

Section: Mmp‐cq12: Is the Concomitant Use Of Oral Steroid And Rituximmentioning

confidence: 99%

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Ujiie

Iwata

Yamagami

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.

show abstract

“…Patients who are non-responders (NR) to standard topical therapies will have to try rituximab as a second option (RTX) [36]. As for patients with ocular cicatricial pemphigoid (OCP), topical medications, such as, topical corticosteroids, are only used as a temporary solution.…”

Section: Recent Advancements and Treatmentsmentioning

confidence: 99%

Mucous membrane pemphigoid: A wide-ranging assessment of various cases and corresponding methods of diagnosis and treatment

Sivri¹,

Chandra²

2018

Med-Science

View full text Add to dashboard Cite

Mucous Membrane Pemphigoid (MMP) is as an infrequent yet tenacious autoimmune blistering disease involving the mucosae of the oral cavity, as well as the conjunctiva, genitals, nasal cavity, pharynx and occasionally the skin. It is seen most commonly in older adults, although cases have been reported throughout early childhood. This review article will provide a thorough explanation of MMP by discussing common misdiagnosis scenarios, presenting rare case reports, and exploring recent treatment options in hopes of spreading awareness for furthering research on diagnosis techniques. The purpose this article is to bring light to the dental community, medical professionals and autoimmune disease researchers, the importance of an early and authentic diagnosis and corresponding methods of recent treatments.

show abstract

Critical analysis of the use of rituximab in mucous membrane pemphigoid: A review of the literature

Cited by 48 publications

References 31 publications

Mucous Membrane Pemphigoid

Mucous Membrane Pemphigoid

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

Mucous membrane pemphigoid: A wide-ranging assessment of various cases and corresponding methods of diagnosis and treatment

Contact Info

Product

Resources

About